

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A04/2018 WB

DESPATCHED ON 05 JUNE 2018

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A3; B44, B35; Cw4, Cw5; DR1, DR4; DQ5, DQ7

					Summary of Results												
					PBL				T-Cells				B-Cells				
					7	7	7	7	29	29	29	29	28	28	28	28	
					0	6	1	1	0	16	1	0	0	18	15	14	
					7	1	6	29	7	13	28	29	28	10	13	14	
					0	0	0	1	1	1	1	1	3	3	3	3	
					0.0%	85.7%	14.3%	14.3%	0.0%	55.2%	3.4%	0.0%	0.0%	64.3%	53.6%	50.0%	
					100.0%	14.3%	85.7%	85.7%	100.0%	44.8%	96.6%	100.0%	100.0%	35.7%	46.4%	50.0%	
Consensus					Negative	Positive	Negative	Negative	Negative	Not Assessed	Negative	Negative	Negative	Not Assessed	Not Assessed	Not Assessed	
HLA Antibody Specificity (Defined By CDC)					DR52	B12 B21	B7	B7 B27 Cw+	DR52	B12 B21	B7	B7 B27 Cw+	DR52	B12 B21	B7	B7 B27 Cw+	
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Without DTT				Without DTT				Without DTT				Comments	
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4		
9	YES	YES	YES	Negative	Positive	Negative	NT	Negative	NT	Negative	Negative	Negative	Positive	NT	Positive	The B cells had poor cell viability. POOR B CELL VIABILITY AND GRANULOCYTE CONTAMINATION, INSUFFICIENT MATERIAL TO REPEAT TESTING. THESE STAND ALONE RESULTS WOULD NOT BE REPORTED CLINICALLY (AB PROFILE, DONOR TYPE, FCXM AND AUTO XM WOULD ALSO BE AVAILABLE, AND LIKELY SUFFICIENT SAMPLE FOR REPEAT TESTING)	
11	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative		
12	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive		
20	YES		YES	Negative	Positive	Positive	Positive					Negative	Positive	Positive	Positive		
23		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		
24		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative		
25		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive		
28		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive		
34		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive		
38	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive		
39		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Unable to report valid results due to number of issues. Cell number was adequate but poor quality. The IgG and IgM positive controls gave weak reactions with scores of 2/4 we expect to see a score of 8. Positive controls did not meet our acceptance criteria and if this was a clinical crossmatch we would repeat.	
41		YES	YES					Negative	Positive	Positive	Negative	Negative	Positive	Positive	Positive		
42	YES		YES	Negative	Positive	Negative	Negative					Negative	Positive	Negative	Negative		
45		YES	YES					Negative	Positive	Negative	Negative	Negative	Negative	Positive	Positive		
51		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative		
54		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive		
58		YES	YES					Negative	Positive	Negative	Negative	Negative	Negative	Positive	Positive		
101		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive		
114		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative		
116		YES	YES					Negative	Positive	Negative	Negative	NT	NT	NT	NT		The viability of the B cells was below sample acceptance criteria.
117	YES		YES	Negative	Positive	Negative	Negative										
136		YES						Negative	Positive	Negative	Negative					After B-cell separation, we did not obtain cells in number and quality acceptables The viability of B cells is low.	
145		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative		
149	YES		YES	Negative	Positive	Negative	Negative										
162		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive		
181		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative		
186		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive		
204		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive		
206		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		
223		YES	YES					Negative	Positive	Negative	Negative	NT	NT	NT	NT	No results reported for B cells without DTT due to low viability.	
227		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative		
269		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative		
284		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Cross match B positif IgG with 2A04 serum2 and B positif IgM with serum3. Low B cell viability	
311		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		
315		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	No results returned	
351		YES	YES														

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A04/2018 WB

DESPATCHED ON 05 JUNE 2018

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	0	2	0		0		0	0	0	2		4	80	80	60
11	1	6	1	1	1	6	1	1	1	1	1	1	90	95	70
12											70	50	95	98	85
20	1	6	2	2					1	6	8	7	90		40
23					1	2	1	1	1	1	1	1		90	30
24					10	80	10	10	20	60	30	30		95	95
25					1	1	1	1	1	2	6	4		99	99
28					1	4	1	1	1	4	8	6		90	85
34					1	1	1	1	1	6	8	8		98	85
38	1	2	1	1	1	8	1	1	1	4	6	6	95	99	97
41						30	30			50	50	80		95	90
42	<10	40-60	<10	<10					<10	40-60	<10	<10	90		90
45					1	6	1	1	1	1	4	4		99	85
51					0	6	0	0	0	6	0	0		90	90
54					<10	30-40	<10	<10	<10	80-90	>90	70-80		99	90
58					<5	15	<5	5	5	5	85	70		95	85
101					1	1	1	1	1	1	1	4			
114					1	1	2	1	1	4	4	2			
116					1	1-6	1	1						90	70
117	1	4	8	6									85		
136					1	6	1	1						98	
145										6-8				100	80
149		2-4											88		
162											4	4		100	100
181					1	8	1	1	1	4	1	1		98	98
186					0	2	0	0	0	4	2	4		99	99
204					1	4	2	1	1	8	6	6		95	95
206					0	0	0	0						95	90
223					1	8	1	1						90	50
227						4				6				90	90
268					1	1	1	1	1	4	1	1		95	80
284					1	2	1	1	1	6	6	2		99	85
311					1	1	1	1	1	1	1	1	90		
315					1	1	1	1	1	1	1	1	80	80	80

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A04/2018 WB

DESPATCHED ON 05 JUNE 2018

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A3; B44, B35; Cw4, Cw5; DR1, DR4; DQ5, DQ7

				Summary of Results												
				PBL				T-Cells				B-Cells				
				7	6	7	6	25	24	26	25	28	26	27	28	
				0	4	0	0	0	14	1	0	0	13	2	4	
				7	2	7	6	25	10	25	25	28	13	25	24	
				0	1	0	1	3	4	2	3	2	4	3	2	
				0.0%	66.7%	0.0%	0.0%	0.0%	58.3%	3.8%	0.0%	0.0%	50.0%	7.4%	14.3%	
				100.0%	33.3%	100.0%	100.0%	100.0%	41.7%	96.2%	100.0%	100.0%	50.0%	92.6%	85.7%	
Consensus				Negative	Not Assessed	Negative	Negative	Negative	Not Assessed	Negative	Negative	Negative	Not Assessed	Negative	Negative	
HLA Antibody Specificity (Defined By CDC)				DR52	B12 B21	B7	B7 B27 Cw+	DR52	B12 B21	B7	B7 B27 Cw+	DR52	B12 B21	B7	B7 B27 Cw+	
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	With DTT				With DTT				With DTT				Comments
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	YES	YES	YES	Negative	Positive	Negative	NT	Negative	NT	Negative	Negative	Negative	Positive	NT	Positive	The B cells had poor cell viability. IgM control failed. Low cell counts. POOR B CELL VIABILITY AND GRANULOCYTE CONTAMINATION. INSUFFICIENT MATERIAL TO REPEAT TESTING. THESE STAND ALONE RESULTS WOULD NOT BE REPORTED CLINICALLY (AB PROFILE, DONOR TYPE, FCXM AND AUTO XM WOULD ALSO BE AVAILABLE, AND LIKELY SUFFICIENT SAMPLE FOR REPEAT Poor T cell viability with DTT serum 1 and 4 not reported. T cell with DTT not reported as IgM control did not react with DTT for T cells. Low number of B cells. Unable to report valid results due to number of issues. Cell number was adequate but poor quality. The IgG and IgM positive controls gave weak reactions with scores of 2/4 we expect to see a score of 8. Positive controls did not meet our acceptance criteria and if this was a clinical crossmatch we would repeat. Insufficient B cells added to sample 2A04 DTT Serum 2 to report. The viability of the B cells was below sample acceptance criteria. Cross match B positif IgG with 2A04 serum 2 and B positif IgM with serum 3. Low B cell viability. No results returned
11	YES	YES	YES	Negative	NT	Negative	Negative	Negative	NT	Negative	Negative	Negative	Negative	Negative	Negative	
12	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
15		YES	YES													
20	YES		YES	Negative	Negative	Negative	Negative									
24		YES	YES					NT	Positive	Negative	NT	Negative	Positive	Negative	Negative	
25		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
28		YES	YES					NT	NT	NT	NT	Negative	Negative	Negative	Negative	
34		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
38	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	NT	Negative	Negative	
39		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	
41		YES	YES					Negative	Positive	Positive	Negative	Negative	Positive	Positive	Positive	
42	YES		YES	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	Positive	Negative	Negative	
45		YES	YES					Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	
51		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
54		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	
58		YES	YES					Negative	Positive	Negative	Negative	Negative	NT	Negative	Negative	
101		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
114		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
116		YES	YES					Negative	Positive	Negative	Negative	NT	NT	NT	NT	
149	YES			Negative	Positive	Negative	Negative									
162		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
181		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
186		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
204		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
206		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
227		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
268		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
284		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
311		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
315		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
351		YES	YES													

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A04/2018 WB

DESPATCHED ON 05 JUNE 2018

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	0	2	0		0		0	0	0	2	0	4	80	80	60
11	1	NT	1	1	1	NT	1	1	1	1	1	1	90	95	70
12													95	98	85
15					0	2	0	0						100	100
20	1	1	1	1					0	0	0	0	90		40
23									1	6	1	6		90	30
24					NT	90	30	NT	30	50	40	40		95	95
25					1	1	1	1	1	1	1	1		99	99
28									1	2	1	1		90	85
34					1	1	1	1	1	1	1	1		98	85
38	1	2	1	1	1	8	1	1	1	0	1	1	95	99	97
41						15	20			40	25	25		95	90
42	<10	40-60	<10	<10					<10	40-60	<10	<10	90		90
45					1	1	1	1	1	1	1	1		99	85
51					0	6	0	0	0	4	0	0		90	90
54					<10	30-40	<10	<10	<20	80-90	70-80	50-60		99	90
58					<5	50	<5	<5	<5		<5	<5		95	85
101					1	1	1	1	1	1	1	1			
114					1	1	1	1	1	1	1	1			
116					1	1-4	1	1						90	70
136														98	
149		2-4											88		
162														100	100
181					1	4	1	1	1	4	1	2		98	98
186					0	2	0	0	0	4	0	0		99	99
204					1	4	1	1	1	6	1	1		95	95
206					0	0	0	0	0	0	0	0		95	95
223														90	50
227						4				6				90	90
268					1	6	1	1	1	4	1	1		95	80
284					1	2	1	1	1	6	1	1		99	85
311					1	1	1	1	1	1	1	1	90		
315					1	1	1	1	1	1	1	1	80	80	80